Cara Therapeutics Inc (CARA)
0.7782
+0.01
(+0.78%)
USD |
NASDAQ |
May 03, 16:00
0.7787
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Gross Profit Margin (Quarterly): 79.76% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 79.76% |
September 30, 2023 | 67.98% |
June 30, 2023 | 79.55% |
March 31, 2023 | 57.99% |
Date | Value |
---|---|
December 31, 2022 | 34.68% |
September 30, 2022 | 71.75% |
June 30, 2022 | |
March 31, 2022 | 56.56% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
34.68%
Minimum
Dec 2022
79.76%
Maximum
Dec 2023
64.04%
Average
67.98%
Median
Sep 2023
Gross Profit Margin (Quarterly) Benchmarks
Nektar Therapeutics | 69.51% |
Stereotaxis Inc | 59.98% |
Cerus Corp | 55.51% |
Avid Bioservices Inc | 7.05% |
Rigel Pharmaceuticals Inc | 89.41% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -108.3% |
Return on Assets | -83.33% |
Return on Invested Capital | -108.3% |
Profit Margin (Quarterly) | -1.08K% |
Operating Margin (Quarterly) | -1.09K% |
Return on Net Operating Assets | -427.4% |